AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.

We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.

Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.

1 North Waukegan Road
North Chicago, IL 60064

Tel: 1-800-255-5162

Visit website

Email Us

Stock Symbol: ABBV
Stock Exchange: NYSE

NEWS

BioMidwest

Top 20 Pharma Companies by Market Cap in Q1 2019

GlobalData recently published their top 20 global pharma companies categorized by market capitalization in the first quarter of 2019.

October 9, 2019

6 min read

Mark Terry

FDA

Expanded Approval for AbbVie’s Mayvret Shortens Treatment Time for Some HCV Patients

AbbVie’s Mayvret won expanded approval from the U.S. Food and Drug Administration to shorten the one-daily treatment duration from 12 to eight weeks in treatment-naïve hepatitis C patients without cirrhosis and with compensated cirrhosis.

September 27, 2019

2 min read

Alex Keown

Bio NC

BioSpace Announces the 2019 Top 30 Life Sciences Ideal Employers

According to the second biennial 2019 Life Sciences Ideal Employer Report by BioSpace, the top three most important attributes cited by life sciences professionals around the world are the opportunity to do interesting and meaningful work, a competitive salary and health benefits.

September 24, 2019

1 min read

BioSpace Staff

Drug Development

Alzheimer’s Disease Insight Report: Current Therapies, Drug Pipeline and Outlook

50 million people worldwide live with symptomatic Alzheimer’s, which has no cure. In honor of September 21st being World Alzheimer’s Day, we evaluated the current therapies, drugs in the pipeline and disease outlook.

September 18, 2019

36 min read

Chelsea Weidman Burke, M.S.

Business

What Makes BioMidwest a Great Place to Live?

The Midwestern region of the United States is often referred to as “flyover country” by residents of both coasts as a way to diminish or dismiss the importance of the states that make up this part of the nation. But the Midwest can be a great place to live and raise a family.

September 9, 2019

4 min read

Alex Keown

Business

Following Rova-T Failure, AbbVie Enters Immuno-Oncology Deal with Idera

Financial terms of the collaboration were not disclosed but shareholders of the Pennsylvania-based company responded favorably.

September 4, 2019

2 min read

Alex Keown

Bio NC

Clinical Catch-Up: August 25-30

Rounding out the traditional summer months, last week had plenty of clinical trial news. Here’s a look at some of the top stories.

August 30, 2019

6 min read

Mark Terry

Drug Development

AbbVie Out $5.8 Billion After Scrapping Rova-T Program

AbbVie announced that the Phase III MERU trial evaluating Rova-T as first-line maintenance therapy for advanced small-cell lung cancer, failed to demonstrate a survival benefit following a pre-planned interim analysis.

August 30, 2019

2 min read

Alex Keown

FDA

FDA Approves AbbVie’s Rinvoq, a Potential Successor to Humira

AbbVie’s JAK inhibitor Rinvoq was approved by the U.S. Food and Drug Administration for the treatment of adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate.

August 19, 2019

3 min read

Alex Keown

JOBS